PA
FATE icon

Profund Advisors’s Fate Therapeutics FATE Stock Holding History

Profund Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-42,652
Closed -$149K – 1137
2024
Q3 		$149K Sell
42,652
-3,876
-8% -$15.1K 0.01% 1083
2024
Q2 		$153K Sell
46,528
-65,823
-59% -$288K 0.01% 1018
2024
Q1 		$825K Buy
+112,351
New +$695K 0.03% 405
2023
Q3 		– Sell
-171,261
Closed -$815K – 1017
2023
Q2 		$815K Sell
171,261
-83,728
-33% -$462K 0.04% 371
2023
Q1 		$1.45M Buy
254,989
+243,798
+2,179% +$1.47M 0.09% 189
2022
Q4 		$113K Buy
11,191
+229
+2% +$4.3K 0.01% 961
2022
Q3 		$246K Sell
10,962
-192
-2% -$5.55K 0.02% 696
2022
Q2 		$276K Sell
11,154
-1,357
-11% -$37.4K 0.02% 692
2022
Q1 		$485K Sell
12,511
-1,400
-10% -$54.2K 0.02% 593
2021
Q4 		$814K Sell
13,911
-1,584
-10% -$89.8K 0.03% 392
2021
Q3 		$918K Buy
15,495
+13,141
+558% +$1.03M 0.03% 389
2021
Q2 		$204K Buy
+2,354
New +$190K 0.01% 1347

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Profund Advisors's FATE Position: Q4 2024 in Review

Profund Advisors sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 42,652 shares — an estimated $149K sold.

Profund Advisors first reported a position in FATE in Q2 2021 and held it in 12 quarters. The position peaked at $1.45M in Q1 2023. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Profund Advisors reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Profund Advisors sold 42,652 Fate Therapeutics shares in Q4 2024, an estimated $149K.
  • Profund Advisors first reported a position in Fate Therapeutics in Q2 2021 and held it in 12 quarters.
  • Profund Advisors's Fate Therapeutics position peaked at $1.45M in Q1 2023.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Profund Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.